Eli Lilly (LLY): FY24 Q4 earnings call, Feb 6, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Feb 6, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
22 matches for “Zepbound”; 5 quoted, at least 25 words apart.
…we received regulatory approvals for Kisunla, Ebglyss, and a new indication for Zepbound in OSA. This progress strengthens our portfolio of new products and enhances…
…more than $3.1 billion, led by a strong uptake of Mounjaro and Zepbound. Q4 also saw a solid performance across oncology, immunology and neuroscience. Our…
…several key pipeline milestones. We received approval for a new indication of Zepbound and Omvoh. We submitted imlunestrant for metastatic breast cancer and tirzepatide for…
…of '23. With more patients using Lilly Direct, the uptake of single-use Zepbound vials increased. We had no wholesaler back orders as we closed 2024,…
…mentioned, our revenue grew 45% in Q4, primarily driven by Mounjaro and Zepbound. Performance of our non-incretin portfolio was also strong as revenue grew 20%,…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-02-06:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-02-06:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP